Related Experiment Video

Updated: Aug 30, 2026

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

Sonnet J H Arlander1, Alex K Eapen, Benjamin T Vroman

  • 1Department of Molecular Pharmacology, Mayo Graduate School, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

The Journal of Biological Chemistry
|October 23, 2003
PubMed

Insights

This study reveals that the molecular chaperone Hsp90 stabilizes the Chk1 protein. Inhibiting Hsp90 disrupts Chk1 signaling, sensitizing tumor cells to chemotherapy by affecting DNA replication stress response.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • DNA damage and replication stress activate the Chk1 signaling pathway, crucial for cell cycle control.
  • Molecular chaperones, like Hsp90, are essential for protein folding, stability, and function.
  • The role of Hsp90 in regulating Chk1 activity during replication stress was previously unknown.

Purpose of the Study:

  • To investigate the interaction between Chk1 and Hsp90.
  • To determine if Chk1 is a client protein of Hsp90.
  • To evaluate the therapeutic potential of inhibiting Hsp90 to sensitize tumor cells to chemotherapy.

Main Methods:

  • Co-immunoprecipitation assays to detect Chk1-Hsp90 interaction.
  • Treatment with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) to assess Chk1 stability.
  • Analysis of Cdc25A degradation and cell sensitivity to gemcitabine.

Main Results:

  • Chk1 was identified as a novel client protein of Hsp90.
  • Inhibition of Hsp90 by 17-AAG led to Chk1 destabilization and impaired Chk1 signaling.
  • Disruption of Chk1 activation by 17-AAG significantly sensitized various tumor cells to gemcitabine.

Conclusions:

  • Chk1 is a client of Hsp90, and its stability is regulated by this chaperone.
  • Pharmacologic inhibition of Hsp90 disrupts Chk1 function during replication stress.
  • Targeting Hsp90 may represent a viable strategy to enhance the efficacy of S phase-active chemotherapeutic agents like gemcitabine.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...